The professor of pediatrics at Stanford Cancer Institute discussed recent data from clinical trials of the lentiviral gene therapy RP-L102.
There were no deaths or safety signals identified by the DSMB for the 3 treated patients in cohort 1.
Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.
No adverse events related to the infusions of stromal cells were reported.
The phase 1 portion of the trial assessing CNA3103 will start enrollment in Australia in the first half of 2023; the phase 2 portion will expand to the US.